The authors of the above manuscript would like to issue a correction notice as below.
Recently we reviewed our own manuscript entitled ''Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register'', originally published in Rheumatology in January 2010, and have identified an error in the calculation of incident rates and incident rate ratios presented in Table 5 . We were able to retrieve the dataset and original statistical files used to generate these results and have identified a programming error. Luckily, the results do not change significantly and the conclusions of the paper are unchanged.
We also identified a small error in the text: the number of skin cancers in our two groups were transposed, and this must have been missed at the point of proof approval. We have subsequently reviewed all of the data presented in this paper and are confident that the rest of the data are accurate. The last sentence of the Results part of the abstract should read:
Over 1776.2 person-years of follow-up (median 3.07 per person), the IRR of SAEs compared with controls was not increased (1.0; 0.8, 1.3).
The penultimate sentence in the Results section should read:
There were 29 reports of skin cancer in total, including 17 basal cell cancers (13 in controls, 4 in anti-TNF), 8 non-melanoma skin cancers not otherwise specified (6 in controls, 2 in anti-TNF) and 4 melanomas (2 in each group). 
